Search results
Showing 61 to 75 of 78 results for metastatic prostate cancer
Hormone-sensitive metastatic prostate cancer: docetaxel (ESUOM50)
This evidence summary has been updated and replaced by NICE guideline NG131.
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)
NICE has developed a medtech innovation briefing (MIB) on Signatera for detecting molecular residual disease from solid tumour cancers .
Evidence-based recommendations on Memokath 051 Ureter stent for ureteric obstruction.
Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]
Discontinued Reference number: GID-TA10779
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Discontinued Reference number: GID-TA11252
This guidance has been updated and replaced by NICE technology appraisal guidance 1110.
This guidance has been updated and replaced by NICE technology appraisal guidance 887.
Discontinued Reference number: GID-TA11163
This guidance has been updated and replaced by NICE technology appraisal guidance 391.
This guidance has been updated and replaced by NICE guideline CG175.
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]
Discontinued Reference number: GID-TA11004
This appraisal has been withdrawn. This is because the marketing authorisation for sipuleucel-T was withdrawn on 19 May 2015.
Thousands could benefit from new take-at-home treatment for advanced prostate cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.
NICE recommends new treatment option for highly active multiple sclerosis
Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.